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ABSTRACT
Drug-induced valvular heart disease (VHD) is a serious side
effect of a few medications, including some that are on the
market. Pharmacological studies of VHD-associated medica-
tions (e.g., fenfluramine, pergolide, methysergide, and caber-
goline) have revealed that they and/or their metabolites are
potent 5-hydroxytryptamine2B (5-HT2B) receptor agonists. We
have shown that activation of 5-HT2B receptors on human heart
valve interstitial cells in vitro induces a proliferative response
reminiscent of the fibrosis that typifies VHD. To identify current
or future drugs that might induce VHD, we screened approxi-
mately 2200 U.S. Food and Drug Administration (FDA)-
approved or investigational medications to identify 5-HT2B
receptor agonists, using calcium-based high-throughput screen-
ing. Of these 2200 compounds, 27 were 5-HT2B receptor agonists
(hits); 14 of these had previously been identified as 5-HT2B recep-
tor agonists, including seven bona fide valvulopathogens. Six of
the hits (guanfacine, quinidine, xylometazoline, oxymetazoline,
fenoldopam, and ropinirole) are approved medications. Twenty-
three of the hits were then “functionally profiled” (i.e., assayed in
parallel for 5-HT2B receptor agonism using multiple readouts to
test for functional selectivity). In these assays, the known valvulo-
pathogens were efficacious at concentrations as low as 30 nM,
whereas the other compounds were less so. Hierarchical cluster-
ing analysis of the pEC50 data revealed that ropinirole (which is not
associated with valvulopathy) was clearly segregated from known
valvulopathogens. Taken together, our data demonstrate that pat-
terns of 5-HT2B receptor functional selectivity might be useful for
identifying compounds likely to induce valvular heart disease.
In 1997, the anorexigen fenfluramine was voluntarily with-
drawn from the U.S. market because of its association with
valvular heart disease (VHD) and pulmonary hypertension
(Connolly et al., 1997). Valve tissue obtained from affected
persons revealed plaques of proliferating myofibroblasts be-
neath the elastic surface of the valves (Steffee et al., 1999). As
lesions develop, valve function becomes impaired and valvular
insufficiency ensues. Indistinguishable histopathologic results
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occur in patients with malignant carcinoid syndrome and in
persons undergoing therapy with certain ergots and ergolines
for migraines (e.g., methysergide, ergotamine) or Parkinson’s
disease [e.g., pergolide, cabergoline (Connolly et al., 1997;
Pritchett et al., 2002; Horvath et al., 2004; Roth, 2007)].
We and others have identified the 5-HT2B receptor as a
likely molecular target for drug-induced VHD based on the
preferentially potent agonism of norfenfluramine (fenflura-
mine’s active metabolite), methysergide, and methylergono-
vine (the active metabolite of ergotamine) at human cloned
5-HT2B receptors (Fitzgerald et al., 2000; Rothman et al.,
2000; Setola et al., 2003). Additional evidence implicating
5-HT2B receptors in drug-induced VHD came from the obser-
vations that 1) 5-HT2B receptors are enriched in heart valve
tissue from various species (Fitzgerald et al., 2000; Setola
et al., 2003; Elangbam et al., 2005; Regard et al., 2008);
2) activation of human valvular interstitial 5-HT2B receptors
is mitogenic, resulting in ERK1/2 phosphorylation and
[3H]deoxythymidine incorporation (Setola et al., 2003); 3) 5-
HT2B receptor activation has been implicated in 5-HT-
induced valvulopathy in experimental animals (Elangbam et
al., 2008); and 4) other drugs with potent 5-HT2B agonist
activity [pergolide, cabergoline, MDMA, 3,4-dimethoxyam-
phetamine (Setola et al., 2003)] induce valvular heart disease
in humans (Droogmans et al., 2007; Schade et al., 2007;
Zanettini et al., 2007), whereas chemically similar drugs
lacking 5-HT2B agonism [e.g., lisuride and bromocriptine
(Roth, 2007; Berger et al., 2009)] are not associated with an
increased risk of VHD (Schade et al., 2007; Zanettini et al.,
2007).
Given the strong associations between 5-HT2B agonism
and drug-induced VHD, we sought first to identify medica-
tions (either approved or investigational) that might induce
VHD. Second, we attempted to determine which signal trans-
duction pathway might be correlated with a drug’s propen-
sity to induce valvulopathy. To achieve the first goal, we
screened a composite library of approximately 2200 approved
or investigational medications and drug-like scaffolds for
5-HT2B receptor agonism using a high-throughput, calcium
flux-based assay done on cells stably expressing exogenous
human 5-HT2B receptors. Subsequently, we measured the
activity of the bona fide agonists using five additional read-
outs of 5-HT2B receptor activation: nuclear factor of activated
T cells (NFAT)-mediated transcription of a -lactamase re-
porter gene, ERK2 phosphorylation, -arrestin recruitment
to agonist-occupied 5-HT2B receptors, accumulation of inosi-
tol phosphates (InsP), and cell proliferation. We reasoned
that the valvulopathogens might share a pattern of func-
tional selectivity (Urban et al., 2007) distinct from the non–
VHD-associated medication ropinirole and/or other 5-HT2B
receptor agonists.
Less than 1% of the compounds screened were 5-HT2B
receptor agonists. Because the identification of 5-HT2B recep-
tor agonists is relatively straightforward, we suggest that
current and candidate drugs be screened for 5-HT2B agonism
before clinical trials and that the clinical use of 5-HT2B
agonist medications be avoided when possible.
Materials and Methods
Plasmid Construct and Cell Lines. Cells stably expressing
human 5-HT2B receptors were generated using the FlpIn system
(Invitrogen Corp., Carlsbad, CA). In brief, a cDNA for the human
5-HT2B receptor was amplified by polymerase chain reaction from
pUSF-5-HT2B (Setola et al., 2005) using 5 and 3 BamHI linkers,
and then subcloned into the BamHI site of pcDNA5.0/Frt to produce
pFlpIn-5-HT2B. Next, subconfluent (60%) FlpIn HEK293 cells in
10-cm dishes were cotransfected with 3 g of pFlpIn-5-HT2B and 3 g
of pOG5 (bearing the Frt recombinase; Invitrogen Corp.) using 30 l
of FuGENE 6 transfection reagent (Roche Applied Science, India-
napolis, IN). Twenty-four hours after transfection, cells were split
1:5 into growth/selection medium (DMEM, 10% FBS, 500 mg/liter
G418, and 50 mg/liter hygromycin B; all from Invitrogen) and al-
lowed to expand. After selection, multiple aliquots of cells at passage
0 were collected, frozen in Cell Recovery Medium (Invitrogen) over-
night at 80 degrees C, then stored in liquid nitrogen. Receptor
expression was verified by 1) radioligand competition binding assays
using [3H]d-lysergic acid diethylamide (1 nM final; PerkinElmer
Life and Analytical Sciences, Waltham, MA) to label 5-HT2B recep-
tors and varying concentrations of unlabeled ligand (spanning at
least 5 orders of magnitude) to compete for radioligand binding
(Setola et al., 2005) and 2) calcium flux assays (see Calcium Flux
Assay) using varying concentrations of 5-HT and BW 723C86 to
measure 5-HT2B receptor activation. Cells were passaged fewer than
10 times beyond passage 0 to ensure stable 5-HT2B receptor expres-
sion. The GeneBlazer cell line (CHO-NFAT-bla) stably expressing
human 5-HT2B receptors was from Invitrogen (Madison, WI) and was
maintained and prepared for assay exactly as described by the
manufacturer.
Calcium Flux Assay. FlpIn HEK239 5-HT2B cells were seeded in
384-well plates at a density of 10,000 cells/well in DMEM containing
1% dialyzed FBS 24 h before the calcium flux assay. The next day,
the cells were incubated (20 l/well) for 1 h at 37°C with Calcium
Plus dye (Molecular Dynamics, Sunnyvale, CA) reconstituted in
FLIPR buffer (Hanks’ balanced salt solution, 2.5 mM probenecid,
and 20 mM HEPES, pH 7.4) (15 ml buffer/bottle of lyophilized dye
yielded a 30 dye stock). After the dye load, cells were placed in a
FLIPRTETRA fluorescence imaging plate reader (Molecular Dynam-
ics); drug dilutions, prepared at 2 final concentration in FLIPR
buffer and aliquotted into 384-well plates, were also added to
the FLIPRTETRA. The fluidics module and plate reader of the
FLIPRTETRA were programmed to read baseline fluorescence for 10 s
(1 read/s), then to add 20 l of drug/well and to read for 6 min
(1 read/s). Fluorescence in each well was normalized to the average
of the first 10 reads (i.e., baseline fluorescence). Then, the maximum
-fold increase, which occurred within 2 to 3 s after drug addition, over
baseline fluorescence elicited by vehicle or drug was determined and
plotted as a function of drug concentration. The data were analyzed
by regression against a three-parameter logistic equation (Prism ver.
4.0; GraphPad Software, San Diego, CA), with the “bottom” shared
for all samples in a plate. Finally, the data were normalized such
that the baseline fluorescence was set to 0% and the Emax for 5-HT
(measured on each plate) was set to 100%.
Transcription Factor Activation Assay. The activation of the
transcription factor NFAT was measured using the GeneBLAzer
HTR2B-NFAT-bla CHO-K1 cell-based assay (Invitrogen Corp.), as
specified by the manufacturer. In brief, cells were seeded in poly-
lysine–coated 96-well plates at approximately 3  104 cells/well 1
day before assay in NFAT-bla assay medium (DMEM, 1% dialyzed
FBS, 0.1 mM nonessential amino acids, and 25 mM HEPES, pH 7.3).
On the day of the assay, dilutions of test compounds and reference
compounds (prepared at 5 final concentration in PBS) were added
to the cells, and plates were incubated for 4 h at 37°C in an atmo-
sphere of 5% CO2. Next, the NFAT--lactamase (bla) FRET sub-
strate was added to the cells and followed by 2-h incubation at room
temperature in the dark. Cleavage of the substrate by bla results in
the loss of FRET activity. Samples were excited at 409 nm and
fluorescence was read from the bottom of the plates on a FlexStation
II plate reader (Molecular Dynamics) at 460 nm (donor fluorescence)
and 530 nm (FRET fluorescence). The ratio of the two fluorescence
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values (460 nm/530 nm) was calculated for each sample. These FRET
ratios were analyzed as above for Ca2 flux assays. The data were
then normalized so that the shared baseline was set to 0%, and the
Emax for 5-HT (measured on each plate) was set to 100%.
Arrestin Translocation Assay. Arrestin recruitment to ligand
activated 5-HT2B receptors was carried out using Tango HTR2B-bla
U2OS cell line (Invitrogen). These cells stably express C-terminally
modified 5-HT2B receptor, protease-tagged -arrestin, and -lacta-
mase reporter gene. Arrestin recruited to the activated receptors was
measured by the amount of -lactamase activity. The cells were
plated in 384-well plates at a density of 104 cells per well in 32 l of
assay medium (DMEM supplemented with 1% dialyzed FBS, 25 mM
HEPES buffer, pH 7.3, 0.1 mM nonessential amino acids, and 1 mM
sodium pyruvate). The cells were stimulated with indicated concen-
tration of the test compounds or reference compound. After overnight
incubation in a humidified incubator at 37°C with 5% CO2, the cells
were loaded with cell-permeable LiveBLAzer FRET B/G substrate
(Invitrogen) for 2 h at room temperature. FRET emission ratios were
obtained on a Tecan Infinite 200 fluorescence plate reader (excitation
at 409 nm, emission 450 nm and 525 nm). The ratio of two fluorescence
values (450 nm/525 nm) was calculated for each sample. The data were
analyzed as described above for transcription factor activation assay.
ERK2 Phosphorylation Assay. The GFP-ERK2 expression vector
was generated by Gateway cloning technology. Entry clone IOH12327
(Invitrogen) encoding ERK2 was recombined with a pLENTI-bsd des-
tination vector modified with an N-terminal EmGFP tag. Using the
resulting pLentiEmGFP-ERK2 construct, lentivirus was generated us-
ing the manufacturer’s recommended protocol (Invitrogen). Gene-
BLAzer HTR2B-NFAT-bla CHO-K1 cells were then transduced with
lentivirus and placed under blasticidin selection. Blasicidin-resistant
clonal populations were isolated by fluorescence-activated cell sort-
ing using GFP fluorescence as a sorting marker. GeneBLAzer
HTR2B-NFAT-bla CHO-K1 GFP-ERK2 cells were seeded in white
384-well flat-bottomed cell culture-treated plates (Corning Life Sci-
ences, Acton, MA) at densities of approximately 2  104 cells/well in
32 l of assay medium (consisting of 99% Opti-MEM, supplemented
with 0.1% charcoal/dextran-treated FBS, 100 U/ml penicillin, and
100 g/ml streptomycin, 0.1 mM nonessential amino acids, 1 mM
sodium pyruvate, 25 mM HEPES pH 7.3, and lacking phenol red). All
media reagents were obtained from Invitrogen. After an overnight
serum-starvation, the cells were exposed to 4 l of antagonist or 1%
DMSO (vehicle) for 10 min. Then, 4 l of serial-diluted test com-
pound was added to each well simultaneously using a Hamamatsu
functional drug screening system instrument (Hamamatsu City, Ja-
pan). Immediately after a 6-min stimulation at room temperature,
cell medium was removed by inverting the plate onto a dry paper
towel. Cells were then lysed by addition of 20 l of lysis buffer/well
(consisting of 2 nM terbium-anti-ERK2 [pThr/pTyr 185/187] anti-
body (Invitrogen), 20 mM Tris-HCl, pH 7.4, 1% Nonidet P-40, 5 mM
EDTA, 5 mM NaF, 150 mM NaCl, and 1:100 of protease and phos-
phatase inhibitor cocktails; Sigma, St. Louis, MO). After allowing the
assay to equilibrate for 2 h at room temperature, time-resolved
FRET emission ratios were determined on a BMG Pherastar fluo-
rescence plate reader (BMG Labtech, Durham, NC) using the follow-
ing settings: excitation at 340 nm, emission at 520 nm and 490 nm;
100-s lag time, 200-s integration time. Emission ratios were then
calculated by dividing the 520 nm emission value by the 490 nm
emission value. Data were then normalized as described above.
Immunoblot Analysis. FlpIn HEK293 5-HT2B cells were plated
in DMEM containing 5% dialyzed FBS. Twenty-four hours later,
cells were washed and incubated in serum-free medium overnight.
Drugs (except 5-HT) were initially dissolved at 10 mM in DMSO and
then diluted in serum-free medium; 5-HT was dissolved directly in
serum-free medium. When necessary, cells were pretreated for 15
min with 1 M SB 206553 before addition of agonist or vehicle.
Agonists were applied at 1 M for 5 min, and then cells were
immediately placed on ice, and lysed in lysis buffer [1.5% CHAPS, 50
mM HEPES, 150 mM NaCl, 1 mM EDTA, 10 mM Na4P2O7, 2 mM
sodium orthovanadate, protease inhibitors (Complete EDTA-free
Protease Cocktail; Roche Applied Science), pH 7.5] for 15 min at 4°C.
Cells were scraped off plates, and the supernatants were collected
after centrifugation. A Bradford protein assay (Bio-Rad Laborato-
ries, Hercules, CA) was performed to determine the protein concen-
tration of each lysate (Bradford, 1976). Samples were diluted to
equal concentrations in sample buffer containing SDS, heated, and
separated by SDS-polyacrylamide gel electrophoresis, followed by
transfer to polyvinylidene difluoride membranes. Blots were blocked
in 3% BSA and probed for pERK with a rabbit anti-pERK antibody
(Cell Signaling Technology, Danvers, MA) at a 1:1000 dilution, fol-
lowed by horseradish peroxidase secondary antibody (1:1000; Vector
Laboratories, Burlingame, CA), and detection as detailed previously
(Sheffler et al., 2006). Blots were then stripped in stripping buffer
containing 100 mM -mercaptoethanol and 2% SDS and reprobed for
total ERK using a rabbit anti-ERK antibody (Cell Signaling Tech-
nology) at 1:1000, followed by secondary antibody and detection as
above. Blots were imaged on a Kodak Gel Logic 2200 (Carestream
Health, Rochester, NY) imager and the bands quantified by densi-
tometry using ImageJ software (http://rsbweb.nih.gov/ij/).
InsP Accumulation Assay. Measurements of InsP accumulation
in agonist-stimulated FlpIn HEK293 5-HT2B cells were made using
the scintillation proximity assay method (Bourdon et al., 2006;
Jensen et al., 2008). In brief, 3  104 cells/well were plated into
96-well tissue culture plates in dialyzed culture medium. The cells
were inositol-starved for 1.5 h and then incubated for 18 h at 37°C
with labeling medium [inositol-free basal media Eagle’s solution]
(Lonza Walkersville, Inc., Walkersville, MD) with 5% dialyzed FBS
and 0.01 Ci/ml [myo-3H]inositol (PerkinElmer Life and Analytical
Sciences)]. Labeling medium was removed and agonists [dissolved in
DMSO and diluted in assay buffer (1 Hanks’ balanced salt solution,
24 mM NaHCO3, 11 mM glucose, and 35 mM LiCl, pH 7.4)] were
added to the cells for 1 h at 37°C. The assay was terminated by
replacement of the incubation medium with 40 l of 50 mM formic
acid. After a 20-min incubation in formic acid to extract the cytosolic
fraction from the cells, the formic acid was incubated with 0.2 mg of
yttrium silicate beads (GE Healthcare, Chalfont St. Giles, Bucking-
hamshire, UK). Radioactivity was measured by scintillation count-
ing using a Wallac MicroBeta TriLux plate reader (PerkinElmer Life
and Analytical Sciences). InsP levels (in disintegrations per minute)
were analyzed as above for Ca2 flux assays. Finally, the data were
normalized such that the shared baseline was set to 0% and the Emax
for 5-HT (measured on each plate) was set to 100%.
Tetrazolium Salt-Based Cell Proliferation Assay. Cell prolif-
eration was assessed using the XTT Cell Proliferation assay (Roche
Applied Science) according to the manufacturer’s recommendations.
Stable FlpIn HEK293-5-HT2B cells or the parental FlpIn HEK293
cells were seeded into poly-L-lysine–coated 96-well plates at density
of 3  104 cells/well and grown for 16 h in DMEM containing 1%
serum (37°C, 5% CO2). Cells were then exposed to various concen-
trations of test or reference compounds for 48 h. During the final 4 h
of treatment, 50 l of XTT tetrazolium salt reagent was added to
each well, and incubation was continued at 37°C. Metabolic mito-
chondrial dehydrogenase activity of the cells converts the tetrazo-
lium salt to a water-soluble formazan dye product, providing a col-
orimetric index proportional to cell number. The formazan dye
absorbance peak at 490 nm was measured using a SpectraMax
microplate reader (Molecular Dynamics). The absorbances obtained
were normalized to the values of untreated cells and expressed as a
percentage.
Statistics. Data were analyzed for statistical significance by two-
way analysis of variance followed by a Bonferroni post test using
Prism 4.0. A p value less than 0.05 was considered significant.
Cluster Analysis. For hierarchical clustering analysis, pEC50
data (expressed as pEC50  5) were clustered using GeneCluster
(http://www.broadinstitute.org/cancer/software/genecluster2/
gc2.html) with “Assays” and “Drugs” representing the two axes. The
similarity matrix used was produced via the correlation (uncentered)
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method, and a complete linkage clustering was performed. The clus-
ter was visualized with Java TreeView ver. 1.13 (http://jtreeview.
sourceforge.net) with a contrast value set at 4.5.
Results
To identify potential valvulopathogenic 5-HT2B receptor
agonists, we compiled a small molecule library of FDA-ap-
proved and investigational drugs and drug-like scaffolds.
This composite library contained the Prestwick Chemical
Library, the National Institutes of Health Clinical Collection,
the National Institute of Mental Health-RTI International
Screening set, and our own internal library (approximately
2200 compounds; see Supplementary Table 1, which contains
all the drugs and the initial screening results). For the initial
screen, we assayed compounds at 3 to 10 M final concen-
tration for agonist activity at recombinant human 5-HT2B
receptors stably expressed in HEK293 FlpIn cells using a
calcium flux-based FLIPR assay. In parallel, we also as-
sessed compound activity in the parental HEK293 FlpIn cells
to identify false positives. From the list of confirmed agonists
(see Supplementary Table 2), several compounds were cho-
sen for further study. The selected compounds were 1) known
5-HT2B agonists, 2) VHD-associated medications and/or me-
tabolites thereof, and/or 3) investigational compounds and
medications not previously known to activate 5-HT2B recep-
tors (Table 1).
We next generated concentration-response isotherms for
the selected, putative 5-HT2B agonists listed in Table 1 to
obtain estimates of potency (pEC50) and efficacy relative to
5-HT (Emax) (Fig. 1, Table 1). It is noteworthy that the cal-
Fig. 1. Agonist concentration-dependent stimulation of calcium flux in FlpIn HEK293 5-HT2B receptor-expressing cells. Maximal intracellular calcium
response to each concentration of agonist, measured by Calcium Plus dye fluorescence, is expressed as a percentage of the 5-HT Emax. Each panel
shows isotherms for two of the drugs listed in Table 1 and for 5-HT. Similar experiments were performed for all drugs listed in Table 1, and the data
were analyzed as described under Materials and Methods to obtain potency (pEC50) and efficacy (Emax) estimates. Parental untransfected FlpIn
HEK293 cells did not exhibit calcium flux responses to any of the tested drugs at any concentration (data not shown).
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cium response for each agonist was blocked by the 5-HT2B/2C
receptor-selective antagonist SB 206553 (Supplementary
Fig. 1). Fourteen of the 27 hits were previously identified
5-HT2B receptor agonists [quipazine, 1-(3-trifluoromethyl-
phenyl) piperazine, RU 24969, SCH 23390, BW723C86, DOI,
WAY 161503, pergolide, norfenfluramine, ergotamine, dihy-
droergotamine, cabergoline, ergonovine, methylergonovine].
Of the 14 known 5-HT2B receptor agonists, 7 were medica-
tions (or metabolites thereof) associated with VHD (pergol-
ide, norfenfluramine, ergotamine, dihydroergotamine, caber-
goline, ergonovine, methylergonovine). The remaining 13
hits were not previously known to be 5-HT2B receptor ago-
nists, although some were known to be functionally active at
other 5-HT receptors (L 694247, SR 57227A, CP 132484-42,
and CP 123,479-11). SKF 83566 was a known D1-like recep-
tor-selective antagonist. Six of the newly discovered 5-HT2B
receptor agonists (guanfacine, quinidine, fenoldopam,
oxymetazoline, xylometazoline, and ropinirole) are currently
approved medications.
On the basis of potency and efficacy estimates in the ago-
nist-induced calcium flux assay, the VHD-associated hits
(pergolide, norfenfluramine, ergotamine, dihydroergotamine,
cabergoline, ergonovine, and methylergonovine) could not be
clearly distinguished from ropinirole, which is thought to be
“safe” in terms of VHD. The VHD-associated drugs cabergo-
line and dihydroergotamine had potencies similar to ropini-
role (pEC50 values of 6.40  0.10, 5.30  0.22, and 5.59 
0.02, respectively) and were as efficacious (Emax values of
98.5  1.9, 81.6  7.9, and 73  1%, respectively) (Table 1).
Other VHD-associated compounds, such as pergolide and
methylergonovine, were more potent (pEC50 values of 7.13 
0.08 and 7.67  0.07, respectively) but not more efficacious
Fig. 2. Agonist concentration-dependent stimulation of a 5-HT2B-mediated NFAT--lactamase reporter. The FRET ratio observed for each concen-
tration of agonist is expressed as a percentage of the 5-HT Emax. Each panel shows isotherms for two of the drugs listed in Table 1 and for 5-HT. Similar
experiments were performed for all drugs listed in Table 1, and the data were analyzed as described under Materials and Methods to obtain potency
(pEC50) and efficacy (Emax) estimates.
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(Emax values of 88.5  6.4 and 49.5  6.7%, respectively)
than ropinirole (Table 1). Thus, we postulated that other
readouts of 5-HT2B receptor activation might better distin-
guish the VHD-associated drugs from ropinirole, and thus
permit us to assess the valvulopathic risk of the other FDA-
approved hits (guanfacine, quinidine, fenoldopam, oxymeta-
zoline, and xylometazoline).
We generated concentration-response isotherms using four
additional assays of 5-HT2B receptor activity as follows: 1)
calcium-sensitive NFAT-mediated transcription of a -lacta-
mase reporter gene, 2) accumulation of InsPs in LiCl-treated
cells, 3) recruitment of -arrestin to agonist-occupied recep-
tors, and 4) phosphorylation of the extracellular signal-reg-
ulated kinase ERK2. In control assays, we established that
these agonist-induced responses were blocked by SB 206553,
and/or absent in parental cell lines not expressing recombi-
nant human 5-HT2B receptors (data not shown). It is note-
worthy that the time scale of the four additional assays—but
not of the calcium flux assay—permits measurement or re-
sponse under equilibrium conditions of agonist-receptor
occupancy.
The -lactamase (bla) assays revealed all VHD-associated
drugs to have pEC50 values greater than 7.5; i.e., they had
EC50 values less than 30 nM (Table 1; representative iso-
therms appear in Fig. 2). In contrast, ropinirole was mark-
edly less potent than known valvulopathogens in bla assays,
having a pEC50 value of 5.0  0.1 (i.e., an EC50 value of 10
M) (Table 1, Fig. 2). The medications guanfacine, oxymeta-
zoline, quinidine, xylometazoline, and fenoldopam had inter-
mediate bla pEC50 values ranging from 6.91  0.06 to 6.00 
Fig. 3. Agonist concentration-dependent stimulation of ERK2 activation (phosphorylation) in U2OS 5-HT2B ERK2-GFP cells. Time-resolved FRET
between ERK2-GFP and a terbium-labeled anti-phospho-ERK2 antibody is measured after 1) a 5-min agonist challenge and 2) a 2-h lysis/antibody
incubation step. The time-resolved FRET observed for each concentration of agonist is expressed as a percentage of the 5-HT Emax. Each panel shows
isotherms for two of the drugs listed in Table 1 and for 5-HT. Similar experiments were performed for all drugs listed in Table 1, and the data were
analyzed as described under Materials and Methods to obtain potency (pEC50) and efficacy (Emax) estimates.
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0.04 (i.e., EC50 values between 123 and 1000 nM) (Table 1,
Fig. 2). Relative efficacy measurements in bla assays did not
distinguish ropinirole (Emax value of 89  6%) from the
VHD-associated compounds dihydroergotamine and methyl-
ergonovine (Emax values of 92  1 and 56  2%, respectively)
(Table 1).
A similar distinction between the VHD-associated drugs
and ropinirole was apparent in the phospho-ERK2 assays.
The valvulopathogens all stimulated ERK2 phosphorylation
with pEC50 values greater than 7.5 (i.e., EC50 values less
than 30 nM) (Table 1; representative isotherms appear in
Fig. 3), whereas ropinirole induced ERK2 phosphorylation
with a pEC50 value of 5.60  0.05 (Table 1, Fig. 3). The
FDA-approved drugs guanfacine, oxymetazoline, quinidine,
xylometazoline, and fenoldopam had pEC50 values for ERK2
phosphorylation ranging from 8.00  0.04 to 6.23  0.03 (i.e.,
EC50 values between 10 and 589 nM) (Table 1, Fig. 3). The
relative efficacy of ropinirole at stimulating ERK2 phosphor-
ylation (Emax value of 67  3%) was not markedly different
from the values for the VHD-associated drugs dihydroergot-
amine and cabergoline (Emax values of 70.6  0.8 and 60.1 
0.9%, respectively) (Table 1).
To validate the results of the ERK2 phosphorylation as-
says, we performed conventional immunoblot analyses. We
focused our attention on the six currently prescribed medi-
cations (guanfacine, oxymetazoline, quinidine, xylometazo-
line, fenoldopam, and ropinirole) and included 5-HT and
norfenfluramine as positive controls. At 1 M after a 5-min
challenge, all drugs stimulated significant ERK1/2 phosphor-
ylation in serum-deprived HEK293 FlpIn cells stably ex-
pressing recombinant human 5-HT2B receptors, as assessed
by immunoblot analysis using an anti-phospho-ERK1/2 an-
tibody (Fig. 4). It is noteworthy that drug-induced ERK1/2
activation was blocked by the 5-HT2B/2C receptor-selective
antagonist SB 206553 (Fig. 4) and was absent in parental
HEK293 FlpIn cells (data not shown).
In -arrestin recruitment assays, the known valvulopatho-
gens were again more potent [pEC50 values ranged from
8.96  0.02 to 6.89  0.05 (i.e., EC50 values between 1.1 and
129 nM)] than ropinirole [pEC50 value 5 (i.e., an EC50 value
Fig. 4. Immunoblot analysis of agonist-mediated
ERK1/2 phosphorylation in FlpIn HEK293 5-HT2B
receptor-expressing cells. A, representative immu-
noblots probed with anti-phospho-ERK1/2 or anti-
total-ERK1/2 antibodies as indicated. B, image
densitometry of immunoblot scans in A to quantify
phospho-ERK1/2 content in cell lysates. Immuno-
reactivity for phospho-ERK1/2 (i.e., mean pixel in-
tensity per region of interest that contained the
p42 and p44 bands, minus the background) was
measured for each sample. Blots were then
stripped and reprobed for total-ERK1/2 and ana-
lyzed as before. The phospho-ERK1/2 immunore-
activity for each sample was normalized to its to-
tal-ERK1/2 immunoreactivity. The normalized
phospho-ERK1/2 immunoractivity elicited by
5-HT (measured on each gel) was set to 100%. SB,
SB-206,553 pretreatment.
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10 M)] (Table 1, Fig. 5). The currently prescribed drugs
guanfacine, oxymetazoline, quinidine, xylometazoline, and
fenoldopam stimulated -arrestin translocation with pEC50
values ranging from 5.51  0.04 to 5.18  0.07 (i.e., EC50
values between 3100 and 6600 nM) (Table 1, Fig. 5). In terms
of relative efficacy, the Emax value of ropinirole in -arrestin
recruitment assays was difficult to estimate because of its
low affinity; however, ropinirole was at least as efficacious as
the valvuopathogen norfenfluramine (Emax value of 52  1%)
(Table 1, Fig. 5). It is noteworthy that for the 23 drugs we
characterized in all five functional assays, partial agonism
(i.e., an Emax value less than 80%) was markedly rarer in
-arrestin translocation assays (4 of 23) than in the other
assays (13 of 23 in calcium flux-based assays, 10 of 23 in bla
assays, 18 of 23 in ERK2 phosphorylation assays, and 12 of
23 in InsP accumulation assays) (Table 1, Figs. 1, 2, 3, 5,
and 6).
As was true in the previous assays, the bona fide VHD-
associated drugs also exhibited greater potencies in InsP
accumulation assays [pEC50 values ranged from 8.64  0.03
to 6.73  0.05 (i.e., EC50 values between 2.3 nM and 186 nM)]
than did ropinirole [pEC50 value was 4.46  0.02 (i.e., an
EC50 value 10 M)] (Table 1, Fig. 6). Ropinirole displayed
an Emax of 163  4% in InsP accumulation assays; as such, it
is more efficacious by this measure than the valvulopathogen
pergolide (Emax value of 95  1%) (Table 1, Fig. 6).
Valves resected from patients with VHD display prolifera-
tive interstitial foci, a hallmark feature of valvulopathy (Con-
Fig. 5. Agonist concentration-dependent stimulation of -arrestin translocation. The FRET ratio observed for each concentration of agonist is
expressed as a percentage of the 5-HT Emax. Each panel shows isotherms for two of the drugs listed in Table 1 and for 5-HT. Similar experiments were
performed for all drugs listed in Table 1, and the data were analyzed as described under Materials and Methods to obtain potency (pEC50) and efficacy
(Emax) estimates.
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nolly et al., 1997; Steffee et al., 1999). The proliferative
plaques precede, and probably contribute to, valve dysfunc-
tion (Roth, 2007). We showed that valvulopathogens elicit
5-HT2B receptor-dependent proliferative responses in pri-
mary cultures of human heart valve interstitial cells, consis-
tent with the putative actions of VHD-associated drugs in
vivo (Setola et al., 2003). Along these lines, we predicted that
the six currently prescribed medications we had identified as
5-HT2B receptor agonists, as well as the known valvulopatho-
gens, would stimulate the proliferation of HEK293 FlpIn
cells stably expressing recombinant human 5-HT2B recep-
tors. In XTT-based proliferation assays, all compounds
seemed to stimulate proliferation at 1 M, an effect that was
blocked by the 5-HT2B/2C receptor selective antagonist SB
206553 (Fig. 7). In terms of apparent potency, 5-HT and the
VHD-associated drugs tested (pergolide, cabergoline, dihy-
droergotamine, and norfenfluramine) were all active at 30
nM in the proliferation assays (Fig. 7A). Furthermore, the
apparent proliferative activity at 30 nM distinguished ropi-
nirole from the known valvulopathogens (Fig. 7A). Of the
other FDA-approved medications tested, only guanfacine and
xylometazoline were active at 30 nM, thus resembling the
valvulopathogens (Fig. 7B). It is noteworthy that none of the
drugs seemed to stimulate proliferation in HEK293 FlpIn
cells not expressing recombinant human 5-HT2B receptors
(Supplemental Fig. 2), ruling out a nonspecific effect (e.g., on
metabolism of the XTT colorimetric substrate).
We finally conducted hierarchical clustering analysis to
determine whether any patterns of functional activity at the
various read-outs of 5-HT2B agonism distinguish bona fide
Fig. 6. Agonist concentration-dependent stimulation of InsP accumulation in FlpIn HEK293 5-HT2B receptor-expressing cells. The InsP accumulation
observed for each concentration of agonist is expressed as a percentage of the 5-HT Emax. Each panel shows isotherms for two drugs listed in Table
1 and for 5-HT. Similar experiments were performed for all drugs listed in Table 1, and the data were analyzed as described under Materials and
Methods to obtain potency (pEC50) and efficacy (Emax) estimates. Note: InsP accumulation stimulated by all tested drugs (at 1 M) was completely
blocked by pretreatment with 10 M SB-206593 (data not shown).
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from potential valvulopathogens. As shown in Fig. 8, ropini-
role (a drug not associated with VHD) was clearly separated
from known VHD-inducing drugs. In addition, ergoline and
ergot-like drugs associated with VHD were all clustered on
the same node. Finally, norfenfluramine was clustered on a
node with 5-HT, indicating a similar pattern of functional
selectivity for these two known valvulopathogens. These re-
sults indicate that ergot and ergoline medications induce a
pattern of functional selectivity at 5-HT2B receptors that is
distinct from that induced by indoleamines and other small
molecules.
Discussion
The major findings of this study are that known valvulo-
pathic 5-HT2B agonists are distinguished by relatively high
potencies across a variety of signaling measures and that
potent 5-HT2B receptor agonism is a relatively rare occur-
rence among drugs and drug-like compounds. In addition,
our results demonstrate that no single pattern of functional
selectivity (Urban et al., 2007) distinguishes bona fide valvu-
lopathic drugs from nonvalvulopathic drugs. On the other
hand, a composite analysis of the signaling data indicates
that ropinirole (a 5-HT2B agonist not associated with VHD)
has a distinctly different pattern of functional selectivity
compared with known VHD-inducing medications.
To arrive at these conclusions, we screened a composite
library containing three publicly available collections of
FDA-approved and investigational medications and one in-
ternally compiled library (approximately 2200 compounds in
all). After removing nonspecific “agonists” (false positives)
from the initial hit list, 27 bona fide 5-HT2B receptor agonists
remained; thus, the validated hit rate was 1.2%. Among the
hits identified in our blinded screen were 1) previously iden-
tified 5-HT2B receptor agonists used in preclinical biomedical
research (e.g., BW 723C86, DOI, WAY 161503) and 2) all
seven VHD-associated medications/metabolites in the com-
posite library (pergolide, norfenfluramine, ergotamine, dihy-
droergotamine, cabergoline, ergonovine, and methylergono-
vine), all of which are reported 5-HT2B receptor agonists
(Fitzgerald et al., 2000; Rothman et al., 2000; Setola et al.,
2003). These findings validate our screening strategy.
Another major finding is the identification of six currently
prescribed medications (guanfacine, oxymetazoline, quini-
dine, xylometazoline, fenoldopam, and ropinirole) as 5-HT2B
receptor agonists. It is noteworthy that, in 2003, we discov-
ered that MDMA, its metabolite 3,4-dimethoxyamphet-
amine, and pergolide were potent 5-HT2B receptor agonists,
Fig. 7. Agonist-mediated proliferation responses in FlpIn HEK293
5-HT2B receptor-expressing cells. XTT-based proliferation assay of ago-
nist-treated FlpIn HEK293 5-HT2B cells. Cells were stimulated for 48 h
with the indicated drug at 1 nM, 30 nM, or 1 M. Four hours before the
end of the drug treatment phase, XTT reagent was added. Then, the
490-nm absorbance (ODmax of the XTT formazan metabolite) was read.
OD490 was proportional to cell number (data not shown). , p  0.05
compared with vehicle (two-way analysis of variance followed by Bonfer-
roni post test). A, VHD-associated drugs were all potent at 30 nM;
ropinirole was distinct from the valvulopathogens in that is was inactive
at 30 nM. B, of the five FDA-approved medications we identified, only
guanfacine and xylometazoline were active at 30 nM.
Fig. 8. Hierarchical clustering analysis reveals a separation between
ropinirole and valvulopathogens. Shown is an image generated by Tree-
View ver. 1.1.3 of pEC50 data derived from Table 1 (see Materials and
Methods for details). The x-axis represents “Assays,” whereas the y-axis
represents “Drugs tested.” Data are colored for activity: 5, black; 9,
yellow.
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and that these drugs stimulated heart valve cell proliferation
in vitro (Setola et al., 2003). Thus, we predicted that MDMA
and pergolide use might be associated with VHD—predic-
tions that were validated in 2007 (Droogmans et al., 2007;
Roth, 2007; Schade et al., 2007; Zanettini et al., 2007). There-
fore, there is precedent for predicting VHD liability based
solely on agonist activity at recombinant 5-HT2B receptors.
In this regard, it is noteworthy that ropinirole, which is
approved for treating Parkinson’s disease and restless legs
syndrome, seems not to induce VHD. If one assumes that
ropinirole is “safe” with respect to valvulopathy, then what
additional factor(s) distinguish VHD-associated 5-HT2B re-
ceptor agonists from 5-HT2B receptor agonists?
The present results suggest that ropinirole is distinct from
the seven known valvulopathic 5-HT2B receptor agonists we
studied in that it is much less potent, albeit not less effica-
cious, than the VHD-associated drugs in all but one of the
5-HT2B receptor functional assays employed. In bla assays,
ropinirole was 526-fold less potent than the least potent
VHD-associated drug (pergolide); in ERK2 phosphorylation
assays, ropinirole was 631-fold less potent than the least
potent valvulopathogen (cabergoline); in -arrestin recruit-
ment assays, ropinirole was 77-fold less potent than the least
potent VHD-inducing compound (norfenfluramine); finally,
in InsP accumulation assays, ropinirole was 301-fold less
potent than the least potent valvulopathic compound (pergol-
ide) (Table 1). In cell proliferation assays, all VHD-associated
drugs elicited a robust response (in terms of the maximum
measured 5-HT response) at 30 nM; ropinirole was active
only at 1 M but not at 30 nM (Fig. 7A). In none of the assays
was there a clear distinction between ropinirole’s relative
efficacy and the relative efficacies of the VHD-associated
drugs. It is not surprising that hierarchical clustering anal-
ysis revealed a clear separation of ropinirole from known
VHD-inducing medications.
Safety and efficacy studies are under way examining the
anorexigen lorcaserin, a 5-HT2C/2B receptor full agonist with
a reported 100-fold selectivity for 5-HT2C receptors over
5-HT2B receptors in vitro (Thomsen et al., 2008). In terms of
VHD risk, the results seem promising: after 12 weeks, daily
lorcaserin use did not seem to have fenfluramine-like valvu-
lopathic liability (Smith et al., 2009). One possible explana-
tion for the apparent safety of lorcaserin is its biodistribu-
tion; in rodents, levels of lorcaserin in the brain exceed
plasma levels by a factor of 13 (Thomsen et al., 2008). As-
suming similar pharmacokinetics and biodistribution in hu-
mans, therapeutic doses of lorcaserin may not generate suf-
ficiently high levels of plasma lorcaserin to activate heart
valve interstitial cell 5-HT2B receptors or other 5-HT2B re-
ceptors relevant to VHD.
In light of our present results, and our previous work
linking 5-HT2B receptor agonists to VHD, we believe it would
be prudent for guanfacine, oxymetazoline, quinidine, xylo-
metazoline, and fenoldopam to be studied further in terms of
their pharmacodynamics to determine whether they are safe
with respect to VHD. Of particular concern are guanfacine
(an antihypertensive agent) and quinidine (an antiarrhyth-
mic agent), each of which is administered over sustained
periods. Furthermore, given the recent FDA approval of
guanfacine for the treatment of ADHD, increasing numbers
of patients (and children) might be exposed to a potentially
valvulopathic agent. Because duration of therapy with VHD-
associated drugs is an important determinant of valvulo-
pathic risk (Connolly et al., 1997; Roth, 2007; Schade et al.,
2007), the short-term use of xylometazoline and oxymetazo-
line (nasal decongestants) and the one-time use of fenoldo-
pam (antihypertensive agent used postoperatively and in-
hospital during hypertensive crisis) may not be as risky.
In conclusion, we report that 5-HT2B receptor agonism is
rare among drugs and drug-like compounds. In addition, we
provide evidence that 5-HT2B receptor agonist potency in
several functional assays might afford a means for separat-
ing compounds likely to induce VHD in humans from those
that are not. Based on our data, we suggest that calcium
flux-based screening is well suited to the initial identification
of 5-HT2B receptor agonists but not to the discrimination of
ones that might induce VHD from ones that are unlikely to do
so. Hierarchical clustering analysis revealed a clear separa-
tion between ropinirole (which is not known to induce VHD)
and other known valvuopathogens when a multiplicity of
functional readouts was considered. Finally, our results sug-
gest that parallel studies of the in vitro pharmacology and
the pharmacokinetics of guanfacine and quinidine and their
metabolites are warranted.
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